FDA Approves AstraZeneca's Baxfendy, Heightening Competition for Mineralys Therapeutics
MLYS has more than doubled off its 52-week low of $12.59.
Summary
AstraZeneca's hypertension drug, Baxfendy (baxdrostat), has received U.S. FDA approval for patients with uncontrolled high blood pressure. This development is significantly negative for Mineralys Therapeutics, as Baxfendy is a direct competitor to Mineralys' lead candidate, lorundrostat, which is currently under U.S. regulatory review with a decision expected in December. AstraZeneca anticipates over $5 billion in peak annual sales for Baxfendy, indicating a substantial market presence. The approval introduces a major, well-resourced competitor into a key therapeutic area for Mineralys, potentially limiting the market opportunity and pricing power for lorundrostat if it is approved. Investors will now closely watch the competitive landscape and the upcoming regulatory decision for lorundrostat.
At the time of this announcement, MLYS was trading at $27.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $12.59 to $47.65. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.